---
title: "On April 19th, Stone Pharmaceutical Group spent HKD 34.5693 million to repurchase 6 million shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/202348156.md"
description: "According to the news from Zhitong Finance APP, Shiyao Group announced that on April 19, 2024, the company spent HKD 34.5693 million to repurchase 6 million shares at a repurchase price of HKD 5.66-5.82 per share"
datetime: "2024-04-19T09:55:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/202348156.md)
  - [en](https://longbridge.com/en/news/202348156.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/202348156.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/202348156.md) | [繁體中文](https://longbridge.com/zh-HK/news/202348156.md)


# On April 19th, Stone Pharmaceutical Group spent HKD 34.5693 million to repurchase 6 million shares

According to the news from Zhitong Finance APP, Stone Pharmaceutical Group (01093) announced that on April 19, 2024, the company spent HKD 34.5693 million to repurchase 6 million shares at a repurchase price of HKD 5.66-5.82 per share

### Related Stocks

- [CSPC PHARMA (01093.HK)](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/en/news/280415449.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/en/news/280502605.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/en/news/281325910.md)
- [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/en/news/280899096.md)
- [CSC Financial Sticks to Their Buy Rating for Longfor Group Holdings (LNGPF)](https://longbridge.com/en/news/280898279.md)